Last reviewed · How we verify
Olumiant
At a glance
| Generic name | Olumiant |
|---|---|
| Also known as | Baricitinib |
| Sponsor | NHS Greater Glasgow and Clyde |
| Target | Casein kinase I isoform gamma-1, Citron Rho-interacting kinase, Mitogen-activated protein kinase kinase kinase 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Alopecia areata
- Atopic dermatitis
- Pneumonia caused by Severe acute respiratory syndrome coronavirus 2
- Rheumatoid arthritis
Common side effects
- Overall Infections
- Viral upper respiratory tract infection
- Upper respiratory tract infection
- Urinary tract infection
- Bronchitis
Serious adverse events
- Serious Infections
- Pneumonia
- Herpes zoster
- Tuberculosis
- Disseminated tuberculosis
- Opportunistic Infections (excluding tuberculosis)
Key clinical trials
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis (PHASE1)
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
- A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) (PHASE3)
- Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) (PHASE2)
- Baricitinib for Reduction of HIV - CNS (PHASE2)
- Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study (PHASE2)
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |